IntelGenx to Report Fourth Quarter and Full Year 2016 Financial Results on March 28, 2017 – Conference Call to Follow
March 21, 2017 (Source) — IntelGenx Technologies Corp., (TSX VENTURE:IGX)(OTCQX:IGXT), today announced that it will release its fourth quarter and full year 2016 financial results after market close on March 28, 2017.
An accompanying conference call will be hosted by Dr. Horst G. Zerbe, President and Chief Executive Officer and Mr. Andre Godin, Executive Vice-President and Chief Financial Officer, to discuss the results and provide a business update. Details of the conference call and webcast are below:
Date: Tuesday, March 28, 2017
Time: 4:30 p.m. ET
Conference ID: 51039225
Webcast Registration: Click here
Get our daily investorintel update
Following the live call, a replay will be available on the Company’s website, www.intelgenx.com, under “Investor Relations”.
IntelGenx is a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilm™ technology platform. Established in 2003, the Montreal-based company is listed on the TSX-V and OTC-QX.
IntelGenx highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx state-of-the-art manufacturing facility, established for the VersaFilm™ technology platform, supports lab-scale to pilot and commercial-scale production, offering full service capabilities to our clients. More information is available about the company at: www.intelgenx.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange), nor the OTCQX accepts responsibility for the adequacy or accuracy of this release.
Source: IntelGenx Technologies Corp.
InvestorIntel is a trusted source of reliable information at the forefront of emerging markets that brings investment opportunities to discerning investors.